Immuron (IMRN) Operating Expenses (2016 - 2024)
Immuron's quarterly Operating Expenses came in at -$1296.2 billion in Q4 2024, down 28164652.89% year-on-year from N/an in Q1 2024, and down 28164652.89% quarter-over-quarter from -$4.6 million in Q4 2023.
Immuron has reported Operating Expenses for 9 years, with the latest figure at -$1296.2 billion in Q4 2024.
- For the quarter ending Q4 2024, Operating Expenses fell 28164652.89% year-over-year to -$1296.2 billion; the trailing twelve-month figure through Sep 2025 stood at -$1296.2 billion (down 28164652.89% YoY), and the FY2025 full-year result was $5.3 million, down 19.47% from the prior year.
- Operating Expenses for Q4 2024 stood at -$1296.2 billion, down from -$4.6 million in the prior quarter.
- The five-year high for Operating Expenses was -$14972.8 in Q4 2021, with the low at -$1296.2 billion in Q4 2024.
- Average Operating Expenses over 5 years is -$216.0 billion, with a median of -$243851.7 recorded in 2020.
- Year-over-year, Operating Expenses jumped 48.82% in 2021 and tumbled 28164652.89% in 2024.
- Tracing IMRN's Operating Expenses over 5 years: stood at -$29252.9 in 2020, then soared by 48.82% to -$14972.8 in 2021, then plunged by 48.38% to -$22217.3 in 2022, then tumbled by 20615.01% to -$4.6 million in 2023, then plunged by 28164652.89% to -$1296.2 billion in 2024.
- The last three Operating Expenses figures came in at -$1296.2 billion (Q4 2024), -$4.6 million (Q4 2023), and -$458450.5 (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,296.23 Bn |
| Dec 31, 2023 | -4.60 Mn |
| Jun 30, 2023 | -458,450.49 |
| Dec 31, 2022 | -22,217.30 |
| Dec 31, 2021 | -14,972.82 |
| Dec 31, 2020 | -29,252.94 |
| Dec 31, 2019 | -30,162.89 |
| Dec 31, 2018 | -2.38 Mn |
| Dec 31, 2017 | -3.27 Mn |
| Dec 31, 2016 | -2.19 Mn |
| Jun 30, 2016 | -3.69 Mn |